PI
DNLI icon

Putnam Investments’s Denali Therapeutics DNLI Stock Holding History

Putnam Investments’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-64,044
Closed -$1.97M – 1151
2022
Q3 		$1.97M Sell
64,044
-232
-0.4% -$7.54K ﹤0.01% 731
2022
Q2 		$1.89M Buy
64,276
+333
+0.5% +$8.72K ﹤0.01% 756
2022
Q1 		$2.06M Sell
63,943
-12,917
-17% -$444K ﹤0.01% 793
2021
Q4 		$3.43M Buy
76,860
+5,159
+7% +$244K ﹤0.01% 654
2021
Q3 		$3.62M Sell
71,701
-17
-0% -$958 0.01% 629
2021
Q2 		$5.63M Buy
71,718
+98
+0.1% +$6.06K 0.01% 490
2021
Q1 		$4.09M Buy
71,620
+25,538
+55% +$1.71M 0.01% 542
2020
Q4 		$3.86M Buy
+46,082
New +$2.79M 0.01% 539

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return